Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy: a Multicenter, Phase II Trial

NCT04318223 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT04318223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04318223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy: a Multicenter, Phase II Trial
Lead sponsor
Consorzio Oncotech
Phase
Phase 2
Overall status
Unknown status
Start date
July 16, 2019
Completion date
July 31, 2023
Enrollment
168 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced breast cancer, metastatic breast cancer